Retraction: Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients (2026)

Peer-Reviewed Study · Anticancer Research Editorial Board (no authors listed) · October 2026

Anticancer Research Editorial Board (no authors listed), 2026-10: Retraction notice for the 197-patient ivermectin/mebendazole cohort. It states that the composite Clinical Benefit Ratio combined non-comparable disease-status categories, lacked a baseline reference point, and could not establish that any benefit preceded exposure; the authors dispute the retraction.

the Editor of Anticancer Research retracts the above article because methodological and analytical problems undermine the reliability of its central clinical-benefit conclusions.

n/a

Anticancer Research Editorial Board (no authors listed), 2026-10: Retraction notice for the 197-patient ivermectin/mebendazole cohort. It states that the composite Clinical Benefit Ratio combined non-comparable disease-status categories, lacked a baseline reference point, and could not establish that any benefit preceded exposure; the authors dispute the retraction. Publisher retraction notice, not a study. It records that no allegation of research misconduct is made and that the decision rests on the measurement and analysis problems described, not on an arithmetic error. The Expression of Concern (MBC-29) and its update remain part of the record. The article remains available and marked retracted. This notice is the latest status as of 2026-11-20. Study type: other.